Jennifer Taher

Jennifer Taher PhD
Assistant Professor
Department of Laboratory Medicine & Pathobiology
Jennifer Taher
Contact Info
T: (416) 586-4800 4526
Sinai Health: Mount Sinai
600 University Ave.
Pathology & Laboratory Medicine
Toronto, ON, M5G 1X8
Appointment Status Primary
Clinical Interests
Clinical Chemistry
Research Interests
Molecular & Cell Biology, Metabolism & Nutrition

Dr Jennifer Taher is a Clinical Biochemist in the Department of Pathology & Laboratory Medicine at Mount Sinai Hospital.

She completed her PhD at the University of Toronto studying the role of glucagon-like peptides in regulation of lipid and lipoprotein metabolism.

She subsequently completed the Post-Doctoral Fellowship in Clinical Chemistry at the University of Toronto.


Research Synopsis

My current research interests include autoimmune disease and healthcare quality improvement.

Publications and Awards

View PubMed search of this faculty member's recent publications.

Recent Publications

Taher, J., Brinc, D., Gilmour, J., Beriault, D. Validating thyroid stimulating hormone (TSH) reflexive testing cutpoints in a tertiary care institution. Clinical Chemistry and Laboratory Medicine. 2019. 18;58(1):e11-e13

Taher, J., Chen, C., Kulasingam, V. A puzzling case of hyperviscosity syndrome. Journal of Applied Laboratory Medicine. 2019. 5(1):209-213

Fiala, C., Taher, J., Diamandis, E. P4 medicine or O4 medicine? Hippocrates provides the answer. Journal of Applied Laboratory Medicine. 2019; 4(1), 108-119

Fiala, C., Taher, J., Diamandis, E. Benefits and harms of wellness initiatives. Clinical Chemistry and Laboratory Medicine. 2019; 57(10), 1494-1500

Taher, J., Cosme, J., Renley, B., Daghfal, D., and Yip, P. A novel Sigma metric encompasses global multi-site performance of 18 assays on the Abbott Alinity system. Clinical Biochemistry. 2018; 63:106-112

Farr, S., Stankovic, B., Hoffman, S., Masoudpoud, H., Baker, C., Taher, J., Zhang, J., Dean, A., Anakk, S., Adeli, K. Bile acid treatment and FXR agonism lower postprandial lipemia in mice. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2020. DOI: 10.1152/ajpgi.00386.2018

Taher, J., Baker, C., Alvarez, D, Ijaz, L., Hussain, M., Adeli, K. GLP-2 increases fasting dyslipidemia and VLDL production through increased hepatic de novo lipogenesis. Endocrinology. 2018; 159(9):3340-3350

Khound, R., Taher, J., Baker, C., Adeli, K., Su, Q. GLP-1 elicits an intrinsic gut-liver metabolic signal in ameliorating diet-induced VLDL overproduction and insulin resistance. Atherosclerosis Thrombosis and Vascular Biology. 2017; 37(12):2252-2259

Taher, J., Farr, S., Adeli, K. Central nervous system regulation of hepatic lipid and lipoprotein metabolism. Current Opinion in Lipidology. 2017; 28:32-38

Zhang, R., Zamani, M., Thiele, C., Taher, J., Alipour, M., Yao, Z., Adeli, K. Ancient ubiquitous protein (AUP1) is a key determinant of hepatic VLDL assembly and secretion. Atherosclerosis Thrombosis and Vascular Biology. 2017. 37(4):633-642

Farr, S., Taher, J., Adeli, K. Central nervous system regulation of intestinal lipid and lipoprotein metabolism. Current Opinion in Lipidology. 2016; 27(1):1-7

Sud, N., Taher, J., Su, Q. MicroRNAs and noncoding RNAs in hepatic lipid and lipoprotein metabolism: potential therapeutic targets of metabolic disorders. Drug Development Research. 2015; 76(6): 318-327

Hsieh, J., Trajcevski, KE., Farr, SL., Baker, CL., Lake, EJ., Taher, J., Iqbal, J., Hussain, M., Adeli, K. Glucagon-like peptide 2 (GLP-2) stimulates postprandial chylomicron production and post-absorptive release of intestinal triglyceride storage pools via induction of nitric oxide signaling in male hamsters and mice. Endocrinology. 2015; 156(10):3538-3547

Adeli, K., Taher, J., Farr, S., Xiao, C., Lewis, G. Chapter 19: Diabetic Dyslipidemia. In Ridgeway, N., McLeod, R. editors. Biochemistry of Lipids, Lipoproteins and Membranes 6th Edition. Oxford UK: Elsevier. 2015. 549-573

Taher J., Baker, C., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., Naples, M., Bourdon, C., Pausova, Z., and Adeli K. GLP-1 Receptor Agonism Ameliorates Hepatic VLDL Overproduction and de novo Lipogenesis in Insulin Resistance. Molecular Metabolism. 2014; 3(9): 823-833